Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Diamedica Therapeutics Inc. (DMAC) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Diamedica Therapeutics Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1401040.
Total stock buying since 2018: $39,932,677.
Total stock sales since 2018: $3,526,971.
Total stock option exercises since 2018: $50,640.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 5,799,999 | $22,758,029 | 0 | $0 | 24,000 | $50,640 |
| 2024 | 2,400,000 | $6,000,000 | 0 | $0 | 0 | $0 |
| 2023 | 2,136,639 | $6,492,445 | 0 | $0 | 0 | $0 |
| 2022 | 3,187,687 | $3,958,071 | 2,855,847 | $3,526,971 | 0 | $0 |
| 2021 | 110,671 | $358,123 | 0 | $0 | 0 | $0 |
| 2020 | 27,000 | $126,001 | 0 | $0 | 0 | $0 |
| 2019 | 42,250 | $115,008 | 0 | $0 | 0 | $0 |
| 2018 | 31,250 | $125,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 1,000,000 | $5,958,033 | 0 | $0 | 0 | $0 |
| 2025-07 | 4,799,999 | $16,799,996 | 0 | $0 | 0 | $0 |
| 2025-04 | 0 | $0 | 0 | $0 | 24,000 | $50,640 |
| 2024-06 | 2,400,000 | $6,000,000 | 0 | $0 | 0 | $0 |
| 2023-11 | 20,000 | $49,200 | 0 | $0 | 0 | $0 |
| 2023-06 | 1,647,889 | $5,693,245 | 0 | $0 | 0 | $0 |
| 2023-04 | 468,750 | $750,000 | 0 | $0 | 0 | $0 |
| 2022-12 | 2,938,618 | $3,632,788 | 2,855,847 | $3,526,971 | 0 | $0 |
| 2022-11 | 41,095 | $49,302 | 0 | $0 | 0 | $0 |
| 2022-07 | 207,974 | $275,981 | 0 | $0 | 0 | $0 |
| 2021-09 | 15,000 | $56,955 | 0 | $0 | 0 | $0 |
| 2021-08 | 95,671 | $301,168 | 0 | $0 | 0 | $0 |
| 2020-12 | 10,000 | $53,700 | 0 | $0 | 0 | $0 |
| 2020-11 | 17,000 | $72,301 | 0 | $0 | 0 | $0 |
| 2019-08 | 19,100 | $49,368 | 0 | $0 | 0 | $0 |
| 2019-05 | 23,000 | $64,972 | 0 | $0 | 0 | $0 |
| 2019-03 | 150 | $668 | 0 | $0 | 0 | $0 |
| 2018-12 | 31,250 | $125,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-27 | Trill Ab | Buy | 50,772 | 6.00 | 304,632 |
| 2025-08-26 | Trill Ab | Buy | 59,648 | 6.00 | 357,888 |
| 2025-08-25 | Trill Ab | Buy | 338,265 | 6.00 | 2,029,251 |
| 2025-08-22 | Trill Ab | Buy | 59,788 | 5.96 | 356,575 |
| 2025-08-21 | Trill Ab | Buy | 48,172 | 5.96 | 287,008 |
| 2025-08-20 | Trill Ab | Buy | 71,107 | 5.86 | 416,473 |
| 2025-08-15 | Trill Ab | Buy | 8,233 | 6.00 | 49,398 |
| 2025-08-14 | Trill Ab | Buy | 70,414 | 5.99 | 421,920 |
| 2025-08-13 | Trill Ab | Buy | 293,601 | 5.91 | 1,734,888 |
| 2025-07-23 | Tomenterprise Private Ab | Buy | 2,857,142 | 3.50 | 9,999,997 |
| 2025-07-23 | Trill Ab | Buy | 1,542,857 | 3.50 | 5,399,999 |
| 2025-07-23 | Jacinto Richard Ii (10% Owner) | Buy | 400,000 | 3.50 | 1,400,000 |
| 2025-04-07 | Pilnik Richard D. (Director) | Option Ex | 24,000 | 2.11 | 50,640 |
| 2024-06-28 | Tomenterprise Private Ab | Buy | 1,200,000 | 2.50 | 3,000,000 |
| 2024-06-28 | Trill Ab | Buy | 1,200,000 | 2.50 | 3,000,000 |
| 2023-11-16 | Wambeke David J. (Chief Business Officer) | Buy | 20,000 | 2.46 | 49,200 |
| 2023-06-23 | Wambeke David J. (Chief Business Officer) | Buy | 38,364 | 3.91 | 150,003 |
| 2023-06-23 | Tomeqt Private Ab | Buy | 1,470,588 | 3.40 | 4,999,999 |
| 2023-06-23 | Semba Charles Pauling (Director) | Buy | 12,787 | 3.91 | 49,997 |
| 2023-06-23 | Pauls Dietrich John (President and CEO) | Buy | 12,787 | 3.91 | 49,997 |
| 2023-06-23 | Pilnik Richard D. (Director) | Buy | 38,363 | 3.91 | 149,999 |
| 2023-06-23 | Giuffre Randall Michael (Director) | Buy | 65,000 | 3.91 | 254,150 |
| 2023-06-23 | Kellen Scott (CFO and Secretary) | Buy | 10,000 | 3.91 | 39,100 |
| 2023-04-10 | Wambeke David J. (Chief Business Officer) | Buy | 468,750 | 1.60 | 750,000 |
| 2022-12-05 | Pilnik Richard D. (Director) | Buy | 35,000 | 1.39 | 48,510 |
| 2022-12-02 | Tomeqt Private Ab | Buy | 2,855,847 | 1.24 | 3,526,971 |
| 2022-12-02 | Tomeqt Private Ab | Sale | 2,855,847 | 1.24 | 3,526,971 |
| 2022-12-01 | Giuffre Randall Michael (Director) | Buy | 46,952 | 1.19 | 56,333 |
| 2022-11-30 | Giuffre Randall Michael (Director) | Buy | 2,970 | 1.19 | 3,534 |
| 2022-11-29 | Giuffre Randall Michael (Director) | Buy | 18,125 | 1.19 | 21,568 |
| 2022-11-16 | Pauls Dietrich John (President and CEO) | Buy | 20,000 | 1.21 | 24,200 |
| 2022-07-08 | Tomenterprise Ab | Buy | 207,974 | 1.33 | 275,981 |
| 2021-09-15 | Alcorn Harry W Jr (SVP, Clinical Operations) | Buy | 15,000 | 3.80 | 56,955 |
| 2021-08-16 | Burroughs Amy L. (Director) | Buy | 44,950 | 3.15 | 141,592 |
| 2021-08-16 | Pauls Dietrich John (President and CEO) | Buy | 5,000 | 3.14 | 15,700 |
| 2021-08-16 | Pilnik Richard D. (Director) | Buy | 15,000 | 3.25 | 48,720 |
| 2021-08-16 | Kellen Scott (CFO and Secretary) | Buy | 10,000 | 3.15 | 31,460 |
| 2021-08-16 | Alcorn Harry W Jr (Senior VP, Clinical Operations) | Buy | 20,721 | 3.07 | 63,696 |
| 2020-12-04 | Pilnik Richard D. (Director) | Buy | 10,000 | 5.37 | 53,700 |
| 2020-11-20 | Giuffre Randall Michael (Director) | Buy | 15,000 | 4.26 | 63,915 |
| 2020-11-09 | Kellen Scott (CFO and Secretary) | Buy | 2,000 | 4.19 | 8,386 |
| 2019-08-19 | Kellen Scott (CFO and Secretary) | Buy | 3,000 | 2.43 | 7,290 |
| 2019-08-16 | Pauls Dietrich John (President and CEO) | Buy | 1,000 | 2.68 | 2,677 |
| 2019-08-16 | Pilnik Richard D. (Director) | Buy | 7,840 | 2.56 | 20,039 |
| 2019-08-16 | Alcorn Harry W Jr (Chief Medical Officer) | Buy | 7,260 | 2.67 | 19,362 |
| 2019-05-31 | Pilnik Richard D. (Director) | Buy | 19,000 | 2.80 | 53,200 |
| 2019-05-24 | Kellen Scott (CFO and Secretary) | Buy | 4,000 | 2.94 | 11,772 |
| 2019-03-27 | Alcorn Harry W Jr (Chief Medical Officer) | Buy | 150 | 4.46 | 668 |
| 2018-12-11 | Xiao Zhenyu (Director) | Buy | 3,250 | 4.00 | 13,000 |
| 2018-12-11 | Pauls Dietrich John (President and CEO) | Buy | 5,000 | 4.00 | 20,000 |
| 2018-12-11 | Pilnik Richard D. (Director) | Buy | 6,250 | 4.00 | 25,000 |
| 2018-12-11 | Verdoorn Todd A. (Chief Scientific Officer) | Buy | 1,000 | 4.00 | 4,000 |
| 2018-12-11 | Parsons James T. (Director) | Buy | 2,250 | 4.00 | 9,000 |
| 2018-12-11 | Giuffre Randall Michael (Director) | Buy | 11,250 | 4.00 | 45,000 |
| 2018-12-11 | Kellen Scott (CFO and Secretary) | Buy | 1,250 | 4.00 | 5,000 |
| 2018-12-11 | Alcorn Harry W Jr (Chief Medical Officer) | Buy | 1,000 | 4.00 | 4,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of DMAC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Diamedica Therapeutics Inc. (symbol DMAC, CIK number 1401040) see the Securities and Exchange Commission (SEC) website.